. Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am J Physiol Heart Circ Physiol 285: H2179-H2187, 2003. First published July 17, 2003 10.1152/ajpheart.00361.2003.-The angiotensin II type 2 (AT2) receptor is upregulated in the left ventricle in heart failure, but its pathophysiological roles in vivo are not understood. In the present study, AT2 receptors were expressed in transgenic (TG) mice using the ventricular-specific myosin light-chain (MLC-2v) promoter. In TG compared with nontransgenic (NTG) mice, in vivo left ventricular (LV) systolic pressure and peak ϩdP/dt were depressed while LV diastolic pressure was elevated (P Ͻ 0.05). Echocardiography showed severely depressed LV fractional shortening, increased systolic and diastolic dimensions, and wall thinning (P Ͻ 0.05). Confocal and electron microscopy studies revealed an increase in the size of myocytes and interstitial spaces as well as an increase in interstitial collagen, disruption of the Z-band, and changes in cytochrome c localization. The changes were most prominent in the highest-expressing TG line, which implies a dose-response relationship. AT2 overexpression was also directly associated with the increase of phosphorylated protein levels of PKC-␣, PKC-␤, and p70S6 kinase. These data demonstrate that ventricular myocytespecific expression of AT2 receptors promotes the development of dilated cardiomyopathy and heart failure in vivo. myosin light-chain promoter; cardiac disease; myocyte ANGIOTENSIN II (ANG II) plays a pivotal role in regulation of the cardiovascular system, and components of the renin-angiotensin system are present in multiple tissues including the heart. At least three subtypes of ANG II receptor have been identified based on differential pharmacological and biochemical properties. These are designated as type 1 (AT 1 in humans, and highly homologous AT 1A and AT 1B in rodents) and type 2 (AT 2 ) receptors. Most of the known vasoconstrictive, inotropic, and growth effects of ANG II are attributable to AT 1 receptors, but the role of the AT 2 receptor in adult heart is enigmatic (20). The expression level of AT 2 receptors is high in developing fetuses but declines rapidly after birth with very low abundance in ventricular myocytes and vascular endothelium and absence in fibroblasts (10, 32).
inotropic, and growth effects of ANG II are attributable to AT 1 receptors, but the role of the AT 2 receptor in adult heart is enigmatic (20) . The expression level of AT 2 receptors is high in developing fetuses but declines rapidly after birth with very low abundance in ventricular myocytes and vascular endothelium and absence in fibroblasts (10, 32) .
However, the AT 2 receptor is expressed in adult hearts under certain pathological conditions. Recent reports suggest that in experimental myocardial infarction in rodents, the AT 2 receptor is acutely upregulated and AT 2 receptor deficiency exacerbates early mortality (2) . In humans with chronic coronary disease in the absence of severe heart failure, the AT 2 receptor does not appear to be upregulated (21) . In contrast, in experimental hypertrophy (17) and chronic severe heart failure in humans (4, 11, 30, 33) , most studies report an increase in AT 2 relative to AT 1 receptors in the ventricle. In vitro, upregulation of the AT 2 receptor is associated with complex effects on growth as well as promotion of apoptosis (9, 34) . Whereas transient AT 2 upregulation after myocardial infarction may be adaptive, the effects of chronic upregulation of AT 2 on ventricular performance and morphology are not yet understood.
To test the hypothesis that chronic AT 2 expression adversely affects chronic cardiac remodeling and function in vivo, we generated lines of transgenic (TG) mice with differing levels of AT 2 receptor expression. AT 2 receptors are not constantly upregulated in the atria of patients with cardiac disease (21, 27) . In addition, expression of AT 2 receptors driven by the ␣-myosin heavy-chain promoter in both ventricles and atria in TG mice is associated with unexpected chronotropic effects (19) that may indirectly modify cardiac workload. These considerations prompted us to develop the reagents necessary to restrict TG expression to the ventricular compartment only. To study the effects of ventricular myocyte-specific expression in the absence of confounding effects in other cardiac chambers or cell compartments, AT 2 expression was driven by the myosin light-chain (MLC-2v) promoter. The aim of this study was to determine whether ventricular myocytespecific overexpression of AT 2 receptors could induce heart failure.
MATERIALS AND METHODS
Generation and screening of TG mice. RNA extracted from Balb/c 18-day embryos was reverse transcribed, and AT 2-specific primers were used to amplify the coding region of the AT 2 receptors (15) . The AT2 cDNA was obtained via RT-PCR and was then subcloned into the MLC-2v promoter vector (Sanbe and Robbins, unpublished data, 2002). The resultant recombinant plasmid was digested with NotI to generate an ϳ8.0-kb DNA fragment that consisted of the MLC-2v promoter and AT 2 cDNA (Fig. 1A) . The DNA fragment was purified and used to generate FVB/n TG mice. The transgene copy number was assessed by Southern blotting. Briefly, tail DNA was digested with HpaI and EcoRI. The resultant DNA fragments were separated on agarose gel, transferred to the membrane, and detected with a transgene-specific cDNA probe. The intensity of the hybridization signal corresponds to the copy number of the transgene. Subsequent studies were performed using 18-wk-old mice. All animal studies were in compliance with the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, National Research Council, Washington, DC: National Academy Press, 1996) .
Quantitative RT-PCR. RNA was prepared from TG and nontransgenic (NTG) mice (n ϭ 15-20/group) using TRI reagent (Sigma). RNA was treated with DNase I (GIBCO-BRL), and 1 g was used for reverse transcription with random primers. Real-time PCR was carried out in a 7700 Sequence Detector (ABI Prism) using AT 2-specific primers (sense, 5-ACATTACCAGCAGCCGTCCT-3; antisense, 5-TGAGCAATTAAAGGCGGACTC-3; Taqman probe, 5-TT-GATAATCTCAACGCAACTGGCACCAA-3). Conditions were as follows: 35 cycles of 94°C for 20 s, 55°C for 20 s, and 72°C for 30 s. Data were analyzed using Sequence Detector 1.7 software. RT-PCR was also carried out to determine expression of the AT 2 transgene and AT1 receptor in TG and NTG mice using 18S as an internal control. PCR was carried out using AT 2-specific primers (sense, 5-CCTGGCAAGCATCT-TATGTAGTT-3; antisense, 5-TTAAGACACAAAGGTGTC-CATTTC-3; fragment size, 623 bp) or AT 1-specific primers (sense, 5-GCATCATCTTTGTGGTGGGAA-3; antisense, 5-GAAGAAAAGCACAATCGCCAT-3). We used 18S primers (Ambion) to amplify 18S as an internal control. Conditions were as follows: 1 cycle of 94°C for 4 min then 28 cycles of 94°C for 1 min, 55°C for 30 s, and 72°C for 30 s. At 28 cycles, band intensity increased exponentially (data not shown); thus the relative band intensity reflects the relative amount of substrate cDNA/mRNA.
Characterization of AT2 receptors. AT2 receptor protein was measured via Western blotting using anti-FLAG antibody (Chemicon) as well as anti-AT2 antibody (a gift from Dr. Robert M. Carey; n ϭ 8-10/group). A radioligand binding assay was performed with crude membranes isolated from left ventricles (n ϭ 25-30/group) as described by Akishita et al. (3) . Membrane fractions (50 g of protein) were incubated at 21°C for 2 h in 200 l of 25 mmol/l Tris ⅐ HCl (pH 7.4) that contained 0.25% BSA and 0.2 nmol/l 125 I-labeled [Sar 1 ,Ile 8 ]ANG II (PerkinElmer) in the absence (for the total count) or presence of 200 mol/l PD-123319 (Sigma). Bound and free ligands were separated with GF/C membrane filters (Millipore). AT2 receptor binding was determined by subtracting the count of samples incubated with PD-123319, which is a specific AT2 antagonist, from the total count. The net radioactivity count was converted to molar values by use of specific activity of the ligand.
Western blot analyses of signaling molecules. Hearts from 18-day embryos and 3-day-, 2-wk-, and 18-wk-old mice were removed, and LV tissues were immediately frozen in liquid nitrogen. Because of the small size of the hearts and the paucity of LV tissue at the early time points, protein samples from LV tissues from 18-day embryos and 3-day-and 2-wkold mice of NTG or TG mice with a high level of AT2 expression (AT 2 high ) were pooled for analysis (n ϭ 3 or 4/group). Densitometry levels of signaling proteins were normalized to densitometry levels of GAPDH, which was used as an internal control. LV protein (50 g) was loaded on SDS-PAGE gels, transferred to nitrocellulose membrane, and probed with phospho-PKC-␣/␤II (Cell Signaling), PKC-␤, PKC-⑀ (BD Transduction Laboratories), phospho-ERK, ERK, phosphop70S6 kinase (p70 S6K ), p70 S6K (Cell Signaling), and GAPDH (CHEMICON) antibodies.
In vivo contractile function. Two-dimensional guided Mmode echocardiography was performed (8) with mice under conscious sedation (chloral hydrate, 200 mg/kg ip). At least 5 Fig. 1 . A: ventricular specific myosin light-chain (MLC-2v)-angiotensin type 2 (AT2) receptor transgene. Structure of the transgene cassette and location of selected restriction sites, PCR primers for identification of transgene, and cDNA probes for Southern blot analysis are shown. H, HpaI; N, NotI; E, EcoRI; S, SalI. MLC-AT2 transgene (ϳ8.0 kb) was excised from the vector as a NotI fragment before microinjection. Exons that encode the MLC-2v 5Ј-untranslated region are shown. B: ventricular-specific overexpression of the MLC-2v-AT2 transgene. AT2-specific primers were used for the detection of both AT2 transgene and endogenous AT2 receptor gene. In all samples, 18S was amplified as an internal control. After 28 cycles of PCR, AT2 mRNA could only be detected in left and right ventricles of the transgenic (TG) mice and was not detected in nontransgenic wildtype (AT2-NTG) mice. sequential beats were analyzed (n ϭ 6-9/group). In vivo LV hemodynamics were assessed (8) by direct LV catheterization (n ϭ 6-12/group).
Microscopic analyses. Myocyte area and length were measured in isolated myocytes as previously described (Ref. 13 ; n ϭ 18-47 myocytes/animal from 5 animals/group). Confocal microscopic examination of phalloidin, cytochrome c, and terminal deoxynucleotidyl transferase end-labeling (TUNEL) staining was performed as previously described (Ref. 8 ; n ϭ 5/group). For immunoelectron microscopy, hearts were prepared for electron microscopy via standard techniques (18) . Thin sections were labeled with a rabbit polyclonal IgG antibody to cytochrome c (sc-7159, Santa Cruz) and tagged with 10 nM goat anti-rabbit colloidal gold. For quantitation of cytochrome c, point counting of 10 photographs of different sections of the ventricle was performed (n ϭ 5 or 6 animals/ group and 11-14 sections/animal).
Statistical analysis. Values are expressed as means Ϯ SE. Comparisons among the groups were analyzed using ANOVA and Tukey's post hoc test. Statistical significance was accepted at the level of P Ͻ 0.05.
RESULTS

Ventricular-specific expression of AT 2 receptors.
The TG construct contained the MLC-2v promoter ligated to the coding sequence of mouse AT 2 receptor (Fig. 1A) . This promoter was initially characterized by MillerHance et al. (23) and drove ventricular-specific expression albeit at low levels. Sanbe and Robbins (unpublished data, 2002) subsequently isolated a 6.2-kbp fragment flanking the 5Ј end of the gene that drives high levels of transgene expression in the ventricles with ratios between 15:1 and 50:1 for ventricular vs. atrial expression. Five founders that contain the AT 2 transgene were produced with copy numbers of 1, 4, 9, 18, and 34. The founder with the highest copy number developed overt heart failure and death during pregnancy. The other lines bred normally and produced the expected numbers of TG offspring, which indicates that AT 2 expression is not lethal or maladaptive during gestation. As expected, the AT 2 transgene was specifi- low TG) levels of AT2 expression. LV overexpression of AT2 transgene protein was detected by Western blotting using FLAG-specific antibody. Protein standards of the indicated molecular masses (kDa) were run in parallel. AT2 TG protein was only detected in LV tissue from TG mice and was not detectable in LV tissue from NTG mice. LV AT2 transgene protein levels were fourfold higher in AT 2 high than in AT 2 low TG mice. AT2 protein levels assessed by AT2-specific antibody were also undetectable in LV tissue from NTG mice and were fourfold higher in AT 2 high than in AT 2 low TG mice (data not shown). B: ligand-binding study of AT2 receptors using membrane fraction prepared from LV tissue in NTG, AT 2 low , and AT 2 high TG mice. AT2-specific binding was negligible in NTG mice and increased 1.25-fold in AT 2 high compared with AT 2 low TG mice. Data are expressed as means Ϯ SE.
cally overexpressed in the left and right ventricles with negligible atrial expression (Fig. 1B) .
To determine the effects of differing levels of ventricular-specific AT 2 overexpression, we compared an AT 2 high line (copy number 18) and a line with a lower level of AT 2 expression (copy number 9, AT 2 low ). Quantitative real-time RT-PCR showed that AT 2 mRNA levels in NTG ventricles were extremely low and could only be detected after 30 cycles of PCR. The mRNA levels of AT 2 receptor in the AT 2 high TG line were 4.04-fold higher than in the AT 2 low TG line. There were no significant differences in LV AT 1 receptor mRNA expression between AT 2 low , AT 2 high , and NTG animals (1.50 Ϯ 0.18, 1.60 Ϯ 0.07 vs. 1.61 Ϯ 0.06 densitometric units; P ϭ not significant).
Consistent with the quantitative real-time RT-PCR observation, LV AT 2 protein was undetectable in NTG mice using anti-AT 2 antibody. The relative level of AT 2 protein in the AT 2 high line was 4.18-and 4.27-fold of that in the AT 2 low line using anti-FLAG antibody ( Fig.  2A ) and anti-AT 2 antibody (data not shown), respectively. The size of AT 2 protein in TG mice was ϳ80 kDa, which is consistent with prior observations (25) . In addition, the AT 2 receptor binding activity was also examined in LV membrane fractions using the method of Akishita et al. (3) . AT 2 -specific binding was extremely low in NTG mice (Fig. 2B) , which corroborates the RT-PCR data and the immunoblotting of AT 2 protein. AT 2 -specific binding was detected in the TG mice, and AT 2 -specific binding in AT 2 high mice was 1.25-fold of that of AT 2 low mice (Fig. 2B) . In vivo LV function. In vivo LV function was assessed by hemodynamic measurements of 18-wk-old NTG and TG mice from the AT 2 high and AT 2 low lines. The time point of 18 wk was selected because initial pilot studies showed the development of clinical signs of overt heart failure (tachypnea and edema) in AT 2 high TG mice. There were no significant differences among the NTG mice from each line, and these data were pooled for analysis. Shown in Table 1 , LV weight and LV wt/body wt were increased in AT 2 high TG compared with NTG mice, whereas these parameters were not increased in AT 2 low mice. In AT 2 high TG compared with NTG mice, LV systolic pressure and peak ϩdP/dt were decreased, and LV end-diastolic pressure was increased; LV developed pressure per gram of LV mass, which is an index of LV pressure development per force-developing unit, was depressed (434 Ϯ 34 vs. 787 Ϯ 34 mmHg/g; P Ͻ 0.01). In AT 2 low TG mice, the values of LV systolic and diastolic function were intermediate between the values of AT 2 high TG and NTG mice (Fig. 3) . The left atria were dilated and left atrium wt/body wt was significantly increased in AT 2 high TG vs. NTG mice. Because AT 2 transgene expression is ventricle restricted, the increase in left atrial mass is likely secondary to the elevation of diastolic filling pressures in both the left ventricle and the left atrium. This was not observed in AT 2 low TG mice, which had better cardiac function and lower LV end-diastolic pressure measurements.
Echocardiography corroborated the presence of LV systolic dysfunction in both TG lines with more severe LV dysfunction in the AT 2 high TG mice (Fig. 4) . As shown in Table 2 , midwall fractional shortening, which is an echocardiographic index of LV systolic function, was depressed in AT 2 low TG mice (22 Ϯ 1 vs. 26 Ϯ 1%; P Ͻ 0.05) and severely depressed in AT 2 high TG mice (13 Ϯ 2 vs. 26 Ϯ 1%; P Ͻ 0.001) compared with NTG mice. Enlargement of LV chamber dimensions, LV wall thinning, and depression of the index of relative wall thickness were present in AT 2 high TG compared with NTG mice, which is indicative of dilated cardiomyopathy. The AT 2 low TG mice were similar to NTG mice with respect to LV dimensions and wall thickness.
Microscopy observations. Analysis of myocyte area and length in isolated myocytes showed that both area and length were increased in myocytes from AT 2 high TG mice whereas myocyte size was not increased in myocytes from AT 2 low TG compared with NTG mice (see Table 1 ). Confocal microscopy showed that LV interstitial spaces from AT 2 high TG mice were enlarged (Fig. 5A, middle) with hypertrophied myocytes that frequently had abnormal intercalated discs evident by confocal microscopy (Fig. 5A, bottom  and insets) . These findings are similar to those previously reported in mice with severe pressure-overload cardiac hypertrophy (8) . Scanning electron microscopy of the hearts from the AT 2 high TG animals also showed enlarged interstitial spaces with increased amounts of fibrillar collagen, which is characteristic of hypertrophied hearts (Fig. 5B, top and  middle) . Similar but not as extensive characteristics of hypertrophy were found in the AT 2 low TG mice.
Initial studies on the occurrence of apoptosis detected by TUNEL staining and confocal microscopy indicated a low prevalence (ϳ0.1%) of apoptosis in the LV myocytes in the free wall of AT 2 high TG animals, but no evidence of apoptosis was observed in the AT 2 low TG or NTG mice (n ϭ 5/group; data not shown).
Consistent with the TUNEL staining, localization of cytochrome c using confocal microscopy suggested that there was a higher concentration of cytochrome c in the cytoplasm of AT 2 high TG animals compared with AT 2 low TG or NTG mice (Fig. 6 ). Transmission electron microscopy (TEM) showed an increased distribution of cytochrome c in the cytoplasm of AT 2 high TG myocytes by immunogold labeling (n ϭ 5 or 6 animals/group and 11-14 sections/animal; Fig. 5B, bottom) . Analysis ( 2 ) of the localization of cytochrome c-positive points in the cytoplasm compared with those localized in the mitochrondria showed that a significantly higher number of positive points were localized in the cytoplasm of AT 2 high TG myocytes compared with AT 2 low TG or NTG mice (P Ͻ 0.05; data not shown). In addition, the TEM micrographs showed disarray of the Z-bands, intercalated discs, and contractile fibers; this is similar to the findings illustrated in Fig. 5A .
Phosphorylation of cardiac signaling proteins. To assess potential signaling mechanisms in AT 2 TG mice, we compared the levels and phosphorylation states of several proteins that are implicated in pathological hypertrophy. In 18-wk-old AT 2 high TG mice compared with NTG mice (Fig. 7) , LV levels of phospho-PKC-␣/ , AT 2 low TG, and AT 2 high TG mice. LV anterior and posterior wall thicknesses were significantly decreased in AT 2 high TG mice and were accompanied by diastolic and systolic LV chamber enlargement. These indices were preserved in AT 2 low TG mice. Midwall fractional shortening was depressed in both TG lines with more severe depression in AT 2 high TG mice. ␤II, which are implicated in the activation of mitogenactivated protein kinase pathway and heart failure (24), were increased (229 Ϯ 20 vs. 100 Ϯ 8%; P Ͻ 0.01). Total PKC-␤ levels were also increased (158 Ϯ 9 vs. 100 Ϯ 10%; P Ͻ 0.01). No change in the level of total PKC-⑀ was found (105 Ϯ 3 vs. 100 Ϯ 10%; P ϭ not significant). In addition, phospho-ERK1/2 levels were increased in AT 2 high TG mice (129 Ϯ 11 vs. 100 Ϯ 4%; P Ͻ 0.05). Phosphorylated levels of its potential downstream target p70 S6K (Thr 421 /Ser 424 ) were markedly elevated (151 Ϯ 16 vs. 100 Ϯ 7%; P Ͻ 0.01), and phosphorylated levels of p85 S6K (Thr 389 ), which is an isoform of p70 S6K , were increased (175 Ϯ 14 vs. 100 Ϯ 6%; P Ͻ 0.01). Total p70 S6K protein levels were also increased (133 Ϯ 8 vs. 100 Ϯ 5%; P Ͻ 0.01). Levels of these signaling proteins in AT 2 low TG were intermediate between those in AT 2 high and NTG mice. To investigate whether the activation of the growthsignaling pathways observed in 18-wk-old AT 2 high TG mice in vivo is directly linked to AT 2 overexpression, levels of these signaling molecules were assessed in LV tissues from 18-day embryos, 3-day-old neonatal mice (an early time point when the AT 2 transgene driven by the MLC-2v promoter is activated), and 2-wk-old mice. The protein levels of signaling molecules in AT 2 high TG mice were expressed as a percentage of NTG levels at each time point. In LV tissues of 18-day AT 2 high TG embryos, no differences were observed compared with NTG embryos. In LV tissues of AT 2 high TG mice, levels of phosphorylated PKC-␣ and PKC-␤II were 154% of NTG in 3-day neonates and 163% of NTG in 2-wk-old animals. Total PKC-␤ and PKC-⑀ levels were not increased at either time point. In AT 2 high TG mice, levels of phosphorylated p70 S6K (Thr 421 /Ser 424 ) were 136 and 131% of 3-day-and 2-wk-old NTG mice, respectively. Levels of phosphorylated p85 S6K (Thr   389   ) were 162 and 164%, and total p70 S6K protein levels were 132 and 138% of 3-day-and 2-wk-old NTG mice, respectively. An increase in the level of phosphorylated ERK1/2, which was observed in 18-wk-old AT 2 high TG mice, was not observed in 3-day-and 2-wk-old AT 2 high TG LV tissue. high TG heart and myocytes are larger than those of the NTG animal. Interstitial spaces (E, white *) are larger and are disrupted compared with the NTG animal, which implicates myocyte loss and replacement with matrix and/or collagen. Intercalated discs (arrows) of myocytes in AT 2 high TG animals (F and insets) are larger than those found in NTG animals (C), and abnormal aggregates of discs were frequently observed. B: electron microscopic analyses. NTG animals (left) and abnormal cardiac morphology of the AT 2 high TG animals (right) are illustrated. Scanning electron microscopy shows that interstitial spaces in the AT 2 high TG animals (D and E) were larger than those found in NTG animals (A and B) and also shows an increased accumulation of fibrillar collagen in the interstitial spaces (E, white arrows; scale bars: A and D, 100 m; B and E, 10 m). Transmission electron microscopy shows increased colloidal gold localization of cytochrome c (black arrows) in the cytoplasm and sarcomeres of AT 2 high TG (F) compared with NTG (C) mice. Disruption of the Z-bands in AT 2 high TG mice is also apparent (scale bar, 500 nm).
DISCUSSION
The major finding of this study is that ventricularspecific expression of the AT 2 receptor can induce heart failure in vivo. TG mice demonstrated dilated cardiomyopathy (1), depressed in vivo LV performance (2) , and pathological myocyte hypertrophy and morphology (3) . Our data confirm that AT 2 receptors are expressed at nearly undetectable levels in normal postnatal ventricles (10, 32) . In contrast, studies of experimental hypertrophy (17) as well as most studies of human failing left ventricles (4, 11, 30, 33) have demonstrated an increase in AT 2 relative to AT 1 receptors. The present study indicates that AT 2 -receptor expression in postnatal ventricular myocardium in vivo exerts a deleterious effect on both ventricular function and morphology. Further, the comparison of two TG lines shows that the magnitude of AT 2 receptor expression predicts the degree of morphological and hemodynamic dysfunction.
AT 2 receptors and growth. In vitro studies of vascular smooth muscle cells (34) , endothelial cells (29) , cardiac fibroblasts, and neonatal cardiomyocytes (5, 31) suggest that the AT 2 receptor inhibits cell growth and proliferation. However, recent reports indicate that AT 2 activation may have the potential to stimulate growth during vascular remodeling (16, 22) as well as in cardiac hypertrophy (26) . Reports of the effects of AT 2 gene deletion on hypertrophic growth in TG mice are conflicting with differing models showing a requirement (12, 28) vs. no effect (3) of the AT 2 receptor on the development of pathological hypertrophy. In TG mice with expression of AT 2 receptors driven by the ␣-MHC promoter, no difference in cardiac size was observed between the TG and NTG mice, whereas cardiac chronotropic properties were modified, which suggests a potential confounding effect of transgene expression in atria (19) . The present study is more precise, and AT 2 receptor expression targeted only to the ventricles by the MLC-2v promoter provides a model to elucidate the effects of expression of the AT 2 receptor on ventricular myocyte remodeling and function.
AT 2 receptors and remodeling. The AT 2 high TG mice, which had severe depression of LV systolic function in vivo, had microscopic findings suggestive of myocyte apoptosis that were accompanied by secondary replacement by fibrillar collagen. Leakage of cytochrome c into the cytoplasm is indicative of cells entering the apoptotic pathway (6) . Both immunogold labeling and confocal localization showed the presence of leakage of cytochrome c into the cytoplasm in the AT 2 high TG mice compared with the AT 2 low TG and NTG mice. These observations are consistent with in vitro observations of the proapoptotic effects of excess AT 2 receptor expression in smooth muscle cells (34) and cardiomyocytes (9) . Morphological as well as hemodynamic abnormalities were less prominent in the AT 2 low TG mice. These observations suggest that the level of AT 2 expression influences the magnitude of both morphological and physiological parameters of heart failure.
Possible mechanisms of remodeling in AT 2 TG mice. We observed that levels of phosphorylated PKC-␣ and -␤ were increased shortly after birth and continued to be elevated at the 18-wk stage of overt heart failure in TG mice that expressed AT 2 . These data support the hypothesis that AT 2 overexpression in vivo in ventricular myocytes is associated with the activation of PKC-␣ and -␤, which are implicated in cardiac remodeling and heart failure (24) . AT 2 overexpression is also associated with the early activation of p70 S6K /p85 S6K and the increase of total levels of p70 S6K protein. These findings are consistent with the observations in one model of AT 2 null mice (12, 28) that showed that deletion of the AT 2 gene prevented hypertrophy caused by chronic ANG II infusion as well as pressure overload. Those studies showed that the absence of LV hypertrophy in AT 2 null mice during pressure overload was related to the reduction of phosphorylated p70 S6K as well as total p70 S6K levels. Those observations contrast with findings in a separate AT 2 null model in which vascular and cardiac hypertrophy was observed to be associated with increased P70 S6K (7) . In the present study, an increase in phosphorylated ERK1/2 was only observed in 18-wk-old animals, which suggests that late activation of this pathway is not directly linked to AT 2 overexpression and is a late secondary response during the progression to heart failure.
In addition, a highly novel mechanism of action of AT 2 receptors was recently proposed by AbdAlla et al. (1) who reported evidence of AT 2 -AT 1 receptor heterodimerization such that AT 2 inhibits activation of AT 1 by direct binding independent of AT 2 activation. This mechanism would provide a complex mode of AT 2 function distinct from signaling cascades activated by ANG II binding to the AT 2 receptor. It is a formal possibility that the FLAG tag itself could cause alterations in protein function; however, the innocuous nature of the tag has been recently documented in a number of contractile protein-based TG mice (14) .
Implications for human cardiac disease. It is not known whether the levels of ventricular myocyte AT 2 expression observed in this TG model simulate or are in excess of that observed in the ventricle in advanced human heart failure. In human cardiac disease, both the regulation and localization of AT 2 are controversial. Regitz-Zagrosek et al. (27) reported no increase in ventricular AT 2 receptors in human heart failure. In contrast, in ventricular tissue from patients with severe heart failure, a downregulation of AT 1 and marked increase in the proportion of AT 2 to AT 1 receptors were reported by Asano et al. (4) using ligand-binding studies and by Haywood et al. (11) using RT-PCR without cell-specific localization. Using autoradiography localization of AT 1 and AT 2 receptors in human heart tissue, both Wharton et al. (33) and Tsutsumi et al. (30) reported a marked upregulation of AT 2 in failing ventricular myocardium in both nonmyocyte and myocyte cell types with a preponderance of its localization in regions with fibrosis. In contrast, Matsumoto et al. (21) found no upregulation of AT 2 receptors in ventricular tissue from patients undergoing bypass surgery with normal or minimally depressed ventricular function and identified AT 2 receptors only in cardiomyocytes but not in fibroblasts.
Summary. Further studies, including in vitro studies in adult myocytes, are required to understand the effects of AT 2 receptor expression on growth, apoptotic signaling, and contractility. The present observations raise the formal possibility that the AT 2 receptor may be a target for intervention in chronic heart failure.
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